Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma
Shigeru Ueda(Kyushu University), Yoshihiko Maehara(Kyushu University), Yuji Soejima(Shinshu University), Hideaki Uchiyama(Kyushu University), Hiroto Kayashima(Kyushu University), Kenji Umeda(Kyushu University), Kazutoyo Morita(Kyushu University), Akinobu Taketomi(Hokkaido University), Ken Shirabe(Gunma University)
Cited by 32
Related Papers
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244